The Pictet-Spengler Reaction Still on Stage.

abstract：:Prostacyclin (PGI(2)) is one of the major vascular protectors against thrombosis and vasoconstriction, caused by thromboxane A(2). Understanding the molecular mechanisms of PGI(2) biosynthesis and signaling is crucial to the development of therapeutic approaches to regulate PGI(2) functions. This review provides infor...

journal_title：Current pharmaceutical design

authors： Ruan KH,Dogné JM

更新日期：2006-01-01 00:00:00

abstract：:The prevalence of hypertension (HTN) worldwide is high and is constantly rising. HTN is considered to be a silent killer since often there are no obvious symptoms but long-term, HTN significantly increases the risk of coronary heart disease and cerebrovascular diseases. Those with diagnosed HTN or at high risk of its ...

journal_title：Current pharmaceutical design

authors： Rysz J,Franczyk B,Banach M,Gluba-Brzozka A

更新日期：2017-01-01 00:00:00

abstract：:There is growing evidence for the involvement of glutamatergic abnormalities in schizophrenia. Uncompetitive NMDA receptor (NMDAR) antagonists induce effects closely resembling both the positive and negative symptoms of schizophrenia; candidate risk genes for schizophrenia converge on the NMDAR expressing synapse; and...

journal_title：Current pharmaceutical design

authors： Stone JM

更新日期：2009-01-01 00:00:00

abstract：:Subjects affected by ischemic heart disease with non-obstructive coronary arteries constitute a population that has received increasing attention over the past two decades. Since the first studies with coronary angiography, female patients have been reported to have non-obstructive coronary artery disease more frequen...

journal_title：Current pharmaceutical design

authors： Bergami M,Scarpone M,Cenko E,Varotti E,Amaduzzi PL,Manfrini O

更新日期：2020-10-12 00:00:00

abstract：:Proper understanding of blood-brain barrier (BBB) regulation is crucial to reduce/prevent its disruption during injury. Since high brain complexity makes interpretation of in vivo data challenging BBB studies are frequently performed using simplified in vitro models. Although such models represent an important and fre...

journal_title：Current pharmaceutical design

authors： Ogunshola OO

更新日期：2011-01-01 00:00:00

abstract：BACKGROUND:A wide class of human diseases and neurodegenerative disorders, such as Alzheimer's disease, is due to the failure of a specific peptide or protein to keep its native functional conformational state and to undergo a conformational change into a misfolded state, triggering the formation of fibrillar cross-β s...

journal_title：Current pharmaceutical design

authors： Ruggeri FS,Habchi J,Cerreta A,Dietler G

更新日期：2016-01-01 00:00:00

abstract：:Quinone based bioreductive drugs have, potentially, a very versatile use in cancer chemotherapy. They can be activated by DT-diaphorase and hence can be used to target tumour types rich in this (O2)-independent reductase enzyme. Small molecular modifications can substantially reduce specificity for DT-diaphorase and u...

journal_title：Current pharmaceutical design

authors： McNally VA,Patterson AV,Williams KJ,Cowen RL,Stratford IJ,Jaffar M

更新日期：2002-01-01 00:00:00

abstract：:Growth differentiation factor 5 (GDF5) is a member of the bone morphogenic protein (BMP) family and plays critical roles in organ development processes including bone, cartilage, ligament, and joint formation. GDF5 is expressed in the cartilage primordium in the early limb development, and in the interzone of joint fo...

journal_title：Current pharmaceutical design

authors： Jin L,Li X

更新日期：2013-01-01 00:00:00

abstract：:"Molecular recognition" is one of the most important molecular processes for living systems in order to maintain their life, since most of the biological functions are initiated with the process. Understanding of the process is also important for designing a new drug. Firstly, it is important to find a target of a dru...

journal_title：Current pharmaceutical design

authors： Phongphanphanee S,Yoshida N,Hirata F

更新日期：2011-01-01 00:00:00

abstract：:The use of systematic approach for the analysis of mechanism of action of drugs at different levels of biological organization of organisms is an important task in experimental and clinical pharmacology for drug designing and increasing the efficacy and safety of drugs. The analysis of published data on pharmacologica...

journal_title：Current pharmaceutical design

authors： Tarasov VV,Kudryashov NV,Chubarev VN,Kalinina TS,Barreto GE,Ashraf GM,Aliev G

更新日期：2018-01-01 00:00:00

abstract：:Treatment of chronic lymphocytic leukemia (CLL) has recently undergone revolutionary changes. Two large randomized trials demonstrated superiority of chemoimmunotherapy combining fludarabine and cyclophosphamide with monoclonal anti-CD20 antibody rituximab (FCR) over fludarabine and cyclophosphamide (FC) alone in firs...

journal_title：Current pharmaceutical design

authors： Smolej L

更新日期：2012-01-01 00:00:00

abstract：:Drug development for neurodegenerative diseases such as Alzheimer's disease (AD) is a challenge, not only due to the cellular molecular mechanisms involved, but also because of the inherent difficulty of most molecules to cross the blood-brain-barrier (BBB). A promising approach to overcome these drawbacks is developi...

journal_title：Current pharmaceutical design

authors： Gomes B,Loureiro JA,Coelho MA,Pereira Mdo C

更新日期：2015-01-01 00:00:00

abstract：:Mitochondria are involved in different physiological and pathological processes that are crucial for tumor cell physiology, growth and survival. Since cancer cells have frequently disrupted different cell death pathways that promote their survival, mitochondria may be key organelles to promote cell death in cancer cel...

journal_title：Current pharmaceutical design

authors： Ferrín G,Linares CI,Muntané J

更新日期：2011-01-01 00:00:00

abstract：:Vascular endothelial growth factor (VEGF) is one of the main endogenous pro-angiogenic cytokines. Inhibition of the VEGF signaling pathways is an effective treatment for cancer patients. In addition, local anti- VEGF therapy was developed and established to treat proliferative diabetic retinopathy, age-related macular...

journal_title：Current pharmaceutical design

authors： van der Giet M,Henkel C,Schuchardt M,Tolle M

更新日期：2015-01-01 00:00:00

abstract：:The tumor cell growth inhibitory activities (log 1/GI(50)) of 166 anticancer agents studied at the National Cancer Institute (NCI) in vitro anticancer screening program have allowed us to analyze the relative importance of physicochemical parameters in influencing the inhibitory activities. Increased molecular weight,...

journal_title：Current pharmaceutical design

authors： Ren SS,Lien EJ

更新日期：2004-01-01 00:00:00

abstract：:Nucleosides constitute an extensive group of natural and chemically modified compounds that display a wide range of structures and activities. Different biocatalysts have been developed for their preparation, but the choice of commercially available enzymes is limited. Therefore, the search of new biocatalysts is part...

journal_title：Current pharmaceutical design

authors： Lewkowicz ES,Iribarren AM

更新日期：2017-10-11 00:00:00

abstract：:Providing novel treatments to help cancer patients live longer and have better lives remains one of the biggest challenges of the pharmaceutical industry. Today much is known about the molecular and genetic causes of cancers thus facilitating the development of novel targeted cancer drugs with improved risk-benefit ra...

journal_title：Current pharmaceutical design

authors： Frieden M,Ørum H

更新日期：2008-01-01 00:00:00

abstract：:Fetal Alcohol Syndrome (FAS), the most severe manifestation of Fetal Alcohol Spectrum Disorder (FASD) is considered the leading non-hereditary cause of mental retardation and neurological deficit in the Western world. There lie a huge associated human cost to both FASD victims and their families and a considerable fin...

journal_title：Current pharmaceutical design

authors： Brennan D,Giles S

更新日期：2014-01-01 00:00:00

abstract：:Alzheimer disease (AD) is characterized by excessive deposition of amyloid beta-peptides (Abeta peptides) in the form of senile plaques as well as neurofibrillary tangles (NFTs) in the brain. In the amyloidogenic pathway, the amyloid-beta precursor protein (APP) is cleaved by beta-secretase first, followed by gamma-se...

journal_title：Current pharmaceutical design

authors： Ziani-Cherif C,Mostefa-Kara B,Brixi-Gormat FZ

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:Enhancing a compound's biological activity is the central task for lead optimization in small molecules drug discovery. However, it is laborious to perform many iterative rounds of compound synthesis and bioactivity tests. To address the issue, it is highly demanding to develop high quality in silico bioacti...

journal_title：Current pharmaceutical design

authors： Ding X,Cui C,Wang D,Zhao J,Zheng M,Luo X,Jiang H,Chen K

更新日期：2020-01-01 00:00:00

abstract：:Among pediatric patients, preterm neonates and newborns are the most vulnerable subpopulation. Rapid developmental changes of physiological factors affecting the pharmacokinetics of drug substances in newborns require extreme care in dose and dose regimen decisions. These decisions could be supported by in silico meth...

journal_title：Current pharmaceutical design

authors： Claassen K,Thelen K,Coboeken K,Gaub T,Lippert J,Allegaert K,Willmann S

更新日期：2015-01-01 00:00:00

abstract：:New biopharmaceutical molecules, potentially able to provide more personalized and effective treatments, are being identified through the advent of advanced synthetic biology strategies, sophisticated chemical synthesis approaches, and new analytical methods to assess biological potency. However, translation of many o...

journal_title：Current pharmaceutical design

authors： Munsell EV,Ross NL,Sullivan MO

更新日期：2016-01-01 00:00:00

abstract：:Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a non-flavonoid polyphenol that may be present in a limited number of foodstuffs such as grapes and red wine. Resveratrol has been reported to exert a plethora of health benefits through many different mechanisms of action. This versatility and presence in the human di...

journal_title：Current pharmaceutical design

authors： Tomé-Carneiro J,Larrosa M,González-Sarrías A,Tomás-Barberán FA,García-Conesa MT,Espín JC

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:The population with autism spectrum disorder (ASD) has been increasing and is currently estimated to be 1 in 58 births. The increased prevalence of ASD together with the lack of knowledge on the processes of aging in this population, the support needed at this stage of life, and the associated risk factors, ...

journal_title：Current pharmaceutical design

authors： Ruggieri V,Gómez JLC,Martínez MM,Arberas C

更新日期：2019-01-01 00:00:00

abstract：:Telomerase is a specialized enzymatic complex responsible for the synthesis of telomeric repeats 5'-TTAGGG-3' localized at the ends of eukaryotic chromosomes. This mechanism prevents shortening of telomeres after each cell division. The enzyme is detected in about 85% of human tumors, but it is not expressed in normal...

journal_title：Current pharmaceutical design

authors： Romaniuk A,Kopczynski P,Ksiazek K,Rubis B

更新日期：2014-01-01 00:00:00

abstract：:Improvements in our understanding of the intrinsic aberrancies in cancer cells have enabled the design and development of novel therapeutics that specifically target these changes. Among the many complex cellular pathways and mechanisms which have been unveiled by new molecular techniques, RAS-mediated signal transduc...

journal_title：Current pharmaceutical design

authors： Nottage M,Siu LL

更新日期：2002-01-01 00:00:00

abstract：:Mesenchymal stem cells (MSCs) were first isolated more than 50 years ago from the bone marrow. Currently MSCs may also be isolated from several alternative sources and they have been used in more than a hundred clinical trials worldwide to treat a wide variety of diseases. The MSCs mechanism of action is undefined and...

journal_title：Current pharmaceutical design

authors： de Girolamo L,Lucarelli E,Alessandri G,Avanzini MA,Bernardo ME,Biagi E,Brini AT,D'Amico G,Fagioli F,Ferrero I,Locatelli F,Maccario R,Marazzi M,Parolini O,Pessina A,Torre ML,Italian Mesenchymal Stem Cell Group

更新日期：2013-01-01 00:00:00

abstract：PURPOSE:The emerging evidence has recently shown an evident dependence between recently identified salusin peptides and atherosclerosis, and their important roles as endogenous modulators of atherogenesis. It was reported that the development of atherosclerosis could also be affected by endogenous salusin- β overproduc...

journal_title：Current pharmaceutical design

authors： Kołakowska U,Kuroczycka-Saniutycz E,Olański W,Wasilewska A

更新日期：2018-01-01 00:00:00

abstract：:NAP (davunetide) is an eight amino acid peptide (NAPVSIPQ) that has been shown to provide potent neuroprotection, in vitro and in vivo. In human clinical trials, NAP has been shown to increase memory scores in patients suffering from amnestic mild cognitive impairment, a precursor to Alzheimer's disease and to enhance...

journal_title：Current pharmaceutical design

authors： Gozes I

更新日期：2011-01-01 00:00:00

abstract：BACKGROUND:Radix Stephaniae Tetrandrine (RST), known as FangJi (Pinyin name) in Chinese, is the dried root of Stephania tetrandra S.Moore, and has been prescribed in combination with other herbs to treat cardiovascular diseases and breast cancer in traditional Chinese medicine (TCM) clinical trials. OBJECTIVE:The aim ...

journal_title：Current pharmaceutical design

authors： Guo Y,Chen B,Pei X,Zhang D

更新日期：2020-01-01 00:00:00